{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:01:36Z","timestamp":1779296496452,"version":"3.51.4"},"reference-count":387,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomaterials"],"abstract":"<jats:p>The broad relationship between the immune system and cancer is opening a new hallmark to explore for nanomedicine. Here, all the common and synergy points between both areas are reviewed and described, and the recent approaches which show the progress from the bench to the beside to biomarkers developed in nanomedicine and onco-immunotherapy.<\/jats:p>","DOI":"10.3390\/nano10071274","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T11:17:17Z","timestamp":1593429437000},"page":"1274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6166-8002","authenticated-orcid":false,"given":"Vanessa","family":"Acebes-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Department of Medicine and Cytometry General Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Landeira-Vi\u00f1uela","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cytometry General Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9435-2952","authenticated-orcid":false,"given":"Pablo","family":"Juanes-Velasco","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cytometry General Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-9918","authenticated-orcid":false,"given":"Angela-Patricia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cytometry General Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Otazo-Perez","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cytometry General Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Manzano-Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Proteomics Unit, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Gongora","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cytometry General Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-3766","authenticated-orcid":false,"given":"Manuel","family":"Fuentes","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cytometry General Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"},{"name":"Proteomics Unit, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"ref_1","unstructured":"Lechuga, L. (2011). Nanomedicina: Aplicaci\u00f3n de la Nanotecnolog\u00eda en la Salud, Digital.csic.es."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Aur\u00eda-Soro, C., Nesma, T., Juanes-Velasco, P., Landeira-Vi\u00f1uela, A., Fidalgo-Gomez, H., Acebes-Fernandez, V., Gongora, R., Parra, M.J.A., Manzano-Roman, R., and Fuentes, M. (2019). Interactions of nanoparticles and biosystems: Microenvironment of nanoparticles and biomolecules in nanomedicine. Nanomaterials, 9.","DOI":"10.20944\/preprints201907.0195.v1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.colsurfa.2013.08.022","article-title":"Nanoparticles-assisted surface charge modification of the porous medium to treat colloidal particles migration induced by low salinity water flooding","volume":"436","author":"Arab","year":"2013","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.apenergy.2014.07.069","article-title":"Nanoparticle technology for heavy oil in-situ upgrading and recovery enhancement: Opportunities and challenges","volume":"133","author":"Hashemi","year":"2014","journal-title":"Appl. Energy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mssp.2013.12.032","article-title":"Facile and rapid production of conductive flexible films by deposition of polythiophene nanoparticles on transparent poly(ethyleneterephthalate): Electrical and morphological properties","volume":"20","author":"Mohammadizadeh","year":"2014","journal-title":"Mater. Sci. Semicond. Process."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.aan.2013.08.010","article-title":"Nanotechnology in Anesthesia and Medicine","volume":"31","author":"Doyle","year":"2013","journal-title":"Adv. Anesth."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/acsnano.6b06040","article-title":"Diverse Applications of Nanomedicine","volume":"11","author":"Pelaz","year":"2017","journal-title":"ACS Nano"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1016\/j.biomaterials.2012.03.063","article-title":"Mechanical properties and biomineralization of multifunctional nanodiamond-PLLA composites for bone tissue engineering","volume":"33","author":"Zhang","year":"2012","journal-title":"Biomaterials"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.2217\/nnm.14.155","article-title":"A promising road with challenges: Where are gold nanoparticles in translational research?","volume":"9","author":"Bao","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmp.2008.05.006","article-title":"Development of phase-contrast X-ray imaging techniques and potential medical applications","volume":"24","author":"Zhou","year":"2008","journal-title":"Phys. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0022-1759(81)90212-X","article-title":"A sol particle agglutination assay for human chorionic gonadotrophin","volume":"45","author":"Leuvering","year":"1981","journal-title":"J. Immunol. Methods"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/smll.200901691","article-title":"Colorimetric Cu 2+ Detection Using DNA-Modified Gold-Nanoparticle Aggregates as Probes and Click Chemistry","volume":"6","author":"Xu","year":"2010","journal-title":"Small"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/ac902492c","article-title":"Enhanced Gold Nanoparticle Based ELISA for a Breast Cancer Biomarker","volume":"82","author":"Ambrosi","year":"2010","journal-title":"Anal. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bios.2018.11.026","article-title":"Cancer diagnosis using nanomaterials based electrochemical nanobiosensors","volume":"126","author":"Sharifi","year":"2019","journal-title":"Biosens. Bioelectron."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1556-276X-8-118","article-title":"Rapid screening and identification of dominant B cell epitopes of HBV surface antigen by quantum dot-based fluorescence polarization assay","volume":"8","author":"Meng","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1021\/ac035493f","article-title":"Real-Time Measurements of Dissolved Oxygen Inside Live Cells by Organically Modified Silicate Fluorescent Nanosensors","volume":"76","author":"Koo","year":"2004","journal-title":"Anal. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3389\/fphar.2018.01230","article-title":"Tumor Microenvironment Targeted Nanotherapy","volume":"9","author":"Fernandes","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/nl4032549","article-title":"Nanoparticles Strengthen Intracellular Tension and Retard Cellular Migration","volume":"14","author":"Tay","year":"2014","journal-title":"Nano Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jconrel.2013.09.026","article-title":"Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice","volume":"172","author":"Stirland","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/smll.200801602","article-title":"Protein-Based Nanomedicine Platforms for Drug Delivery","volume":"5","author":"MaHam","year":"2009","journal-title":"Small"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1039\/C7NR02196H","article-title":"Functional insights into the cellular response triggered by a bile-acid platinum compound conjugated to biocompatible ferric nanoparticles using quantitative proteomic approaches","volume":"9","author":"Murillo","year":"2017","journal-title":"Nanoscale"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1517\/17425247.2015.1049530","article-title":"Calcium carbonate nanoparticles as cancer drug delivery system","volume":"12","author":"Zarrintan","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"28042","DOI":"10.18632\/oncotarget.25556","article-title":"Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study","volume":"9","author":"Magherini","year":"2018","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-014-0055-3","article-title":"In vitro assessment of antibody-conjugated gold nanorods for systemic injections","volume":"12","author":"Centi","year":"2014","journal-title":"J. Nanobiotechnol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/acsmedchemlett.9b00007","article-title":"Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer","volume":"10","author":"Marzo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/adma.201404788","article-title":"Tunable Rigidity of (Polymeric Core)-(Lipid Shell) Nanoparticles for Regulated Cellular Uptake","volume":"27","author":"Sun","year":"2015","journal-title":"Adv. Mater."},{"key":"ref_29","first-page":"1031","article-title":"Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science 80"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1021\/nn402201w","article-title":"Enhanced Retention and Cellular Uptake of Nanoparticles in Tumors by Controlling Their Aggregation Behavior","volume":"7","author":"Liu","year":"2013","journal-title":"ACS Nano"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.nano.2012.01.003","article-title":"Peptide PHSCNK as an integrin \u03b15\u03b21 antagonist targets stealth liposomes to integrin-overexpressing melanoma","volume":"8","author":"Dai","year":"2012","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1002\/anie.200504599","article-title":"Laser-Induced Release of Encapsulated Materials inside Living Cells","volume":"45","author":"Skirtach","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/anie.201206696","article-title":"Light-Addressable Capsules as Caged Compound Matrix for Controlled Triggering of Cytosolic Reactions","volume":"52","author":"Ochs","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature12401","article-title":"Stretchable nanoparticle conductors with self-organized conductive pathways","volume":"500","author":"Kim","year":"2013","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/nl050637m","article-title":"Carbon Nanotube Substrates Boost Neuronal Electrical Signaling","volume":"5","author":"Lovat","year":"2005","journal-title":"Nano Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1385\/JMN:14:3:175","article-title":"Molecular Functionalization of Carbon Nanotubes and Use as Substrates for Neuronal Growth","volume":"14","author":"Mattson","year":"2000","journal-title":"J. Mol. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1021\/nn305559j","article-title":"Carbon-Nanotube-Embedded Hydrogel Sheets for Engineering Cardiac Constructs and Bioactuators","volume":"7","author":"Shin","year":"2013","journal-title":"ACS Nano"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/smll.200801242","article-title":"Notch Ligand Presenting Acellular 3D Microenvironments for ex vivo Human Hematopoietic Stem-Cell Culture made by Layer-By-Layer Assembly","volume":"5","author":"Lee","year":"2009","journal-title":"Small"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-006-9132-0","article-title":"Micellar Nanocarriers: Pharmaceutical Perspectives","volume":"24","author":"Torchilin","year":"2006","journal-title":"Pharm. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1021\/ja071090b","article-title":"A Protein Nanocarrier from Charge-Conversion Polymer in Response to Endosomal pH","volume":"129","author":"Lee","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1039\/c2cs15337h","article-title":"Biological applications of magnetic nanoparticles","volume":"41","author":"Colombo","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_42","first-page":"787","article-title":"Carbon Nanotubes--the Route Toward Applications","volume":"297","author":"Baughman","year":"2002","journal-title":"Science 80"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17604","DOI":"10.1021\/ja0567081","article-title":"Bright Fluorescent Nanodiamonds: No Photobleaching and Low Cytotoxicity","volume":"127","author":"Yu","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nnano.2010.231","article-title":"The emerging field of RNA nanotechnology","volume":"5","author":"Guo","year":"2010","journal-title":"Nat. Nanotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1021\/ac200853a","article-title":"Analyzing Nanomaterial Bioconjugates: A Review of Current and Emerging Purification and Characterization Techniques","volume":"83","author":"Sapsford","year":"2011","journal-title":"Anal. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/thno.29431","article-title":"Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy","volume":"9","author":"Gao","year":"2019","journal-title":"Theranostics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jconrel.2009.10.014","article-title":"Size and shape effects in the biodistribution of intravascularly injected particles","volume":"141","author":"Decuzzi","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","article-title":"Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles","volume":"31","author":"He","year":"2010","journal-title":"Biomaterials"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.biomaterials.2013.10.009","article-title":"Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells","volume":"35","author":"Heo","year":"2014","journal-title":"Biomaterials"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1021\/acsnano.7b09041","article-title":"Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination","volume":"12","author":"Yang","year":"2018","journal-title":"ACS Nano"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific t cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16686","DOI":"10.1021\/jacs.6b09538","article-title":"Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer","volume":"138","author":"Duan","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.nano.2017.04.006","article-title":"Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer","volume":"13","author":"Liu","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"30619","DOI":"10.1038\/srep30619","article-title":"Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13193","article-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.7150\/thno.37216","article-title":"Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy","volume":"9","author":"Zhuang","year":"2019","journal-title":"Theranostics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.biomaterials.2013.11.004","article-title":"Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-polylactide","volume":"35","author":"Chen","year":"2014","journal-title":"Biomaterials"},{"key":"ref_58","first-page":"1","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.04.043","article-title":"Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer","volume":"61","author":"Rahimian","year":"2015","journal-title":"Biomaterials"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1021\/ma00064a011","article-title":"Self-Aggregates of Hydrophobized Polysaccharides in Water. Formation and Characteristics of Nanoparticles","volume":"26","author":"Akiyoshi","year":"1993","journal-title":"Macromolecules"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1021\/nn502975r","article-title":"Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity","volume":"8","author":"Muraoka","year":"2014","journal-title":"ACS Nano"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jconrel.2013.03.025","article-title":"Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses","volume":"168","author":"Li","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbrc.2007.12.112","article-title":"Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy","volume":"367","author":"Shimizu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s12274-016-1035-8","article-title":"NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors","volume":"9","author":"Curnis","year":"2016","journal-title":"Nano Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acsnano.7b05299","article-title":"Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy","volume":"11","author":"Meir","year":"2017","journal-title":"ACS Nano"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1802479","DOI":"10.1002\/adma.201802479","article-title":"Large-Pore Mesoporous-Silica-Coated Upconversion Nanoparticles as Multifunctional Immunoadjuvants with Ultrahigh Photosensitizer and Antigen Loading Efficiency for Improved Cancer Photodynamic Immunotherapy","volume":"30","author":"Ding","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1517\/17425247.5.6.703","article-title":"Mannose-targeted systems for the delivery of therapeutics","volume":"5","author":"Irache","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biomaterials.2015.11.040","article-title":"Self-adjuvanted nanovaccine for cancer immunotherapy: Role of lysosomal rupture-induced ROS in MHC class I antigen presentation","volume":"79","author":"Wang","year":"2016","journal-title":"Biomaterials"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1800139","DOI":"10.1002\/adtp.201800139","article-title":"A Viral Nanoparticle Cancer Vaccine Delays Tumor Progression and Prolongs Survival in a HER2 + Tumor Mouse Model","volume":"2","author":"Shukla","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/1078-0432.CCR-11-3358","article-title":"Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein","volume":"19","author":"Crane","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2217\/imt.12.26","article-title":"Particle-mediated delivery of cytokines for immunotherapy","volume":"4","author":"Christian","year":"2012","journal-title":"Immunotherapy"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and beyond in Cancer Immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V65.3.644.644","article-title":"Treatment of Hairy Cell Leukemia With Recombinant Alpha2 Interferon","volume":"65","author":"Ratain","year":"1985","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the Treatment of Cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V65.6.1349.bloodjournal6561349","article-title":"A clinical trial of anti-idiotype therapy for B cell malignancy","volume":"65","author":"Meeker","year":"1985","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.4049\/jimmunol.161.6.3176","article-title":"Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors","volume":"161","author":"Tutt","year":"1998","journal-title":"J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1073\/pnas.95.2.652","article-title":"Fc receptors are required in passive and active immunity to melanoma","volume":"95","author":"Clynes","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: At last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.cji.0000203081.43235.d7","article-title":"Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: Mechanism of antibody-dependent cellular cytotoxicity and impact of human serum","volume":"29","author":"Lefebvre","year":"2006","journal-title":"J. Immunother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship","volume":"64","author":"Tartas","year":"2004","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrc3366","article-title":"Controlling escape from angiogenesis inhibitors","volume":"12","author":"Sennino","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Benmebarek, M.R., Karches, C.H., Cadilha, B.L., Lesch, S., Endres, S., and Kobold, S. (2019). Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061283"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.seminoncol.2015.05.005","article-title":"Adoptive Cell Therapy\u2014Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors","volume":"42","author":"Feldman","year":"2015","journal-title":"Semin. Oncol."},{"key":"ref_96","first-page":"1318","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science 80"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor\u2013transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e26914","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2018.01740","article-title":"CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies","volume":"9","author":"Knochelmann","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines. Past, present, and future","volume":"Volume 119","author":"Guo","year":"2013","journal-title":"Advances in Cancer Research"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Pan, R.-Y., Chung, W.-H., Chu, M.-T., Chen, S.-J., Chen, H.-C., Zheng, L., and Hung, S.-I. (2018). Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. J. Immunol. Res., 2018.","DOI":"10.1155\/2018\/4325874"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"ref_109","first-page":"144","article-title":"Phase I Study with an Autologous Tumor Cell Vaccine for Locally Advanced or Metastatic Prostate Cancer","volume":"10","author":"Berger","year":"2007","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/S0264-410X(00)00485-0","article-title":"Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: First randomized phase III trials show promise","volume":"Volume 19","author":"Hanna","year":"2001","journal-title":"Proceedings of the Vaccine"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1479-5876-5-43","article-title":"Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: First clinical experience and evidence of an immune response","volume":"5","author":"Winter","year":"2007","journal-title":"J. Transl. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1990.8.11.1858","article-title":"Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients","volume":"8","author":"Berd","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0022-5347(05)65071-9","article-title":"Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma","volume":"167","author":"Antonia","year":"2002","journal-title":"J. Urol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"h988","DOI":"10.1136\/bmj.h988","article-title":"Cancer vaccines","volume":"350","author":"Butterfield","year":"2015","journal-title":"BMJ"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000658-199210000-00010","article-title":"Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine","volume":"Volume 216","author":"Morton","year":"1992","journal-title":"Proceedings of the Annals of Surgery"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4161\/hv.20740","article-title":"Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer","volume":"8","author":"Hanna","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e24523","DOI":"10.4161\/onci.24523","article-title":"Prostate cancer vaccines update on clinical development","volume":"2","author":"Geary","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: Current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nri1592","article-title":"Dendritic cells as therapeutic vaccines against cancer","volume":"5","author":"Banchereau","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anticancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3389\/fimmu.2018.02265","article-title":"Dendritic cell cancer therapy: Vaccinating the right patient at the right time","volume":"9","author":"Bloemendal","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1084\/jem.176.6.1693","article-title":"Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte\/macrophage colony-stimulating factor","volume":"176","author":"Inba","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.0.CO;2-B","article-title":"Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen","volume":"29","author":"Murphy","year":"1996","journal-title":"Prostate"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-10-3421","article-title":"Peptide-loaded langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo","volume":"17","author":"Romano","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with Mage-3A1 peptide-pulsed nature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/0008-5472.CAN-03-3505","article-title":"Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma","volume":"64","author":"Yu","year":"2004","journal-title":"Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-5347(01)61767-1","article-title":"Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells","volume":"161","author":"Rieser","year":"1999","journal-title":"J. Urol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1517\/14712590802517970","article-title":"Oncophage: Step to the future for vaccine therapy in melanoma","volume":"8","author":"Tosti","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_133","first-page":"1513","article-title":"L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: A review","volume":"6","author":"Xia","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.2174\/092986709789909648","article-title":"Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives","volume":"16","author":"Mocellin","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0167-5699(92)90198-G","article-title":"The immune system evolved to discriminate infectious nonself from noninfectious self","volume":"13","author":"Janeway","year":"1992","journal-title":"Immunol. Today"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1749-6632.2000.tb05521.x","article-title":"Mammaglobin, a Breast-Specific Gene, and Its Utility as a Marker for Breast Cancer","volume":"923","author":"FLEMING","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e1456603","DOI":"10.1080\/2162402X.2018.1456603","article-title":"Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming","volume":"7","author":"Johnson","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molonc.2011.01.006","article-title":"Tyrosinase related protein 1 (TYRP1\/gp75) in human cutaneous melanoma","volume":"5","author":"Ghanem","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.seminoncol.2012.02.013","article-title":"Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy","volume":"39","author":"Osada","year":"2012","journal-title":"Semin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1080\/21645515.2015.1035502","article-title":"DNA vaccines, electroporation and their applications in cancer treatment","volume":"11","author":"Lee","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/imt-2016-0146","article-title":"Neoepitopes as cancer immunotherapy targets: Key challenges and opportunities","volume":"9","author":"Brennick","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0065-230X(08)60318-8","article-title":"Peptide-binding heat shock proteins in the endoplasmic reticulum: Role in immune response to cancer and in antigen presentation","volume":"62","author":"Srivastava","year":"1993","journal-title":"Adv. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.seminoncol.2012.02.007","article-title":"Whole cell vaccines\u2014Past progress and future strategies","volume":"39","author":"Keenan","year":"2012","journal-title":"Semin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines3020344","article-title":"Whole tumor antigen vaccines: Where are we?","volume":"3","author":"Chiang","year":"2015","journal-title":"Vaccines"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","article-title":"Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2015.01.003","article-title":"TCR affinity for p\/MHC formed by tumor antigens that are self-proteins: Impact on efficacy and toxicity","volume":"33","author":"Stone","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_148","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","article-title":"Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers","volume":"92","author":"Gillison","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Wang, X.G., Revskaya, E., Bryan, R.A., Strickler, H.D., Burk, R.D., Casadevall, A., and Dadachova, E. (2007). Treating Cancer as an Infectious Disease\u2014Viral Antigens as Novel Targets for Treatment and Potential Prevention of Tumors of Viral Etiology. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0001114"},{"key":"ref_152","first-page":"124","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science 80"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4161\/onci.19727","article-title":"Targeting the tumor mutanome for personalized vaccination therapy","volume":"1","author":"Kreiter","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_156","first-page":"69","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science 80"},{"key":"ref_157","first-page":"1337","article-title":"Targeting of cancer neoantigens with donor-derived T cell receptor repertoires","volume":"352","author":"Toebes","year":"2016","journal-title":"Science 80"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_159","first-page":"243","article-title":"A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules","volume":"267","author":"Rock","year":"1995","journal-title":"Science 80"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/SQB.1989.054.01.003","article-title":"Approaching the asymptote? Evolution and revolution in immunology","volume":"Volume 54","author":"Janeway","year":"1989","journal-title":"Proceedings of the Cold Spring Harbor Symposia on Quantitative Biology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e998538","DOI":"10.1080\/2162402X.2014.998538","article-title":"Consensus nomenclature for CD8+ T cell phenotypes in cancer","volume":"4","author":"Apetoh","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-016-0160-y","article-title":"Adjuvants for peptide-based cancer vaccines","volume":"4","author":"Khong","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nature14211","article-title":"Cancer immunotherapy: Dendritic-cell vaccines on the move","volume":"519","author":"Sabado","year":"2015","journal-title":"Nature"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Lee, H.T., Lee, S.H., and Heo, Y.S. (2019). Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules, 24.","DOI":"10.3390\/molecules24061190"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/1078-0432.CCR-15-2944","article-title":"Ipilimumab combined with nivolumab: A standard of care for the treatment of advanced melanoma?","volume":"22","author":"Carlino","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.21147\/j.issn.1000-9604.2018.02.01","article-title":"Future of anti-PD-1\/PD-L1 applications: Combinations with other therapeutic regimens","volume":"30","author":"Song","year":"2018","journal-title":"Chin. J. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11912-018-0740-8","article-title":"Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers","volume":"20","author":"Liu","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: Response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in Cancer Immunotherapy","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_177","first-page":"399","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"Nasrallah","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: Moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","article-title":"Delivering safer immunotherapies for cancer","volume":"114","author":"Milling","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Song, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T.J., Li, J., Dorosheva, O., Liu, T., Liu, R., and Huang, L. (2018). Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat. Commun., 9.","DOI":"10.1038\/s41467-018-04605-x"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1073\/pnas.1018382108","article-title":"Multistage nanoparticle delivery system for deep penetration into tumor tissue","volume":"108","author":"Wong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"McNamara, M.A., Nair, S.K., and Holl, E.K. (2015). RNA-Based Vaccines in Cancer Immunotherapy. J. Immunol. Res., 2015.","DOI":"10.1155\/2015\/794528"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1021\/acsnano.7b00978","article-title":"Efficient Nanovaccine Delivery in Cancer Immunotherapy","volume":"11","author":"Zhu","year":"2017","journal-title":"ACS Nano"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1021\/acs.nanolett.8b00390","article-title":"Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival","volume":"18","author":"Kozielski","year":"2018","journal-title":"Nano Lett."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1021\/acs.nanolett.8b02340","article-title":"Immunomodulating Nanomedicine for Cancer Therapy","volume":"18","author":"Liu","year":"2018","journal-title":"Nano Lett."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1021\/acs.nanolett.6b04071","article-title":"Improving T Cell Expansion with a Soft Touch","volume":"17","author":"Lambert","year":"2017","journal-title":"Nano Lett."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nnano.2017.54","article-title":"Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence","volume":"12","author":"Xue","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41551-016-0011","article-title":"In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy","volume":"1","author":"Wang","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1021\/acs.nanolett.7b03734","article-title":"Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation","volume":"17","author":"Hickey","year":"2017","journal-title":"Nano Lett."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41565-018-0146-7","article-title":"Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy","volume":"13","author":"Chiang","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nnano.2017.69","article-title":"Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy","volume":"12","author":"Yuan","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2217\/nnm-2016-0102","article-title":"Post isolation modification of exosomes for nanomedicine applications","volume":"11","author":"Hood","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.3390\/ijms15034142","article-title":"Exosomes derived from mesenchymal stem cells","volume":"15","author":"Yu","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nrc2543","article-title":"Tetraspanins: Push and pull in suppressing and promoting metastasis","volume":"9","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri2567","article-title":"Membrane vesicles as conveyors of immune responses","volume":"9","author":"Ostrowski","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/wnan.1174","article-title":"A systematic approach to exosome-based translational nanomedicine","volume":"4","author":"Hood","year":"2012","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.4161\/onci.20897","article-title":"Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands","volume":"1","author":"Munich","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"8146","DOI":"10.4049\/jimmunol.180.12.8146","article-title":"Induction of Exosome Release in Primary B Cells Stimulated via CD40 and the IL-4 Receptor","volume":"180","author":"Saunderson","year":"2008","journal-title":"J. Immunol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pmic.201000422","article-title":"Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery","volume":"11","author":"Raimondo","year":"2011","journal-title":"Proteomics"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cr.2008.282","article-title":"Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases","volume":"18","author":"Chen","year":"2008","journal-title":"Cell Res."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-018-0403-9","article-title":"Recent advancements in the use of exosomes as drug delivery systems","volume":"16","author":"Bunggulawa","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"ref_212","first-page":"257","article-title":"Phenotypic modulation of auto-reactive cells by insertion of tolerogenic molecules via MSC-derived exosomes","volume":"3","author":"Mokarizadeh","year":"2012","journal-title":"Vet. Res. Forum Int. Q. J."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.addr.2012.07.001","article-title":"Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery","volume":"65","author":"Yeo","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.imlet.2012.06.001","article-title":"Microvesicles derived from mesenchymal stem cells: Potent organelles for induction of tolerogenic signaling","volume":"147","author":"Mokarizadeh","year":"2012","journal-title":"Immunol. Lett."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1089\/scd.2013.0479","article-title":"Mesenchymal stem cells secrete immunologically active exosomes","volume":"23","author":"Zhang","year":"2014","journal-title":"Stem Cells Dev."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.canlet.2011.10.002","article-title":"Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo","volume":"315","author":"Zhu","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Lee, J.K., Park, S.R., Jung, B.K., Jeon, Y.K., Lee, Y.S., Kim, M.K., Kim, Y.G., Jang, J.Y., and Kim, C.W. (2013). Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0084256"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1093\/nar\/gks463","article-title":"Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes","volume":"40","author":"Wahlgren","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.nano.2014.03.014","article-title":"Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages","volume":"10","author":"Bala","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"20360","DOI":"10.3402\/jev.v2i0.20360","article-title":"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research","volume":"2","author":"Witwer","year":"2013","journal-title":"J. Extracell. Vesicles"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","article-title":"A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy","volume":"35","author":"Tian","year":"2014","journal-title":"Biomaterials"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nano.2017.09.011","article-title":"Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: In vitro and in vivo evaluations","volume":"14","author":"Kim","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1084\/jem.183.3.1161","article-title":"B lymphocytes secrete antigen-presenting vesicles","volume":"183","author":"Raposo","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm0598-594","article-title":"Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes","volume":"4","author":"Zitvogel","year":"1998","journal-title":"Nat. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.molmed.2017.05.003","article-title":"Exosomes as Reconfigurable Therapeutic Systems","volume":"23","author":"Conlan","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/85438","article-title":"Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming","volume":"7","author":"Wolfers","year":"2001","journal-title":"Nat. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.nano.2013.06.015","article-title":"Nanoscale artificial antigen presenting cells for T cell immunotherapy","volume":"10","author":"Perica","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","article-title":"CD8+ T Cells: Foot Soldiers of the Immune System","volume":"35","author":"Zhang","year":"2011","journal-title":"Immunity"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T Cell Activation","volume":"27","author":"Koretzky","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.1021\/acsnano.5b02829","article-title":"Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy","volume":"9","author":"Perica","year":"2015","journal-title":"ACS Nano"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive Strategies that are Mediated by Tumor Cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nmat2442","article-title":"Understanding biophysicochemical interactions at the nano-bio interface","volume":"8","author":"Nel","year":"2009","journal-title":"Nat. Mater."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.12129","article-title":"Human cell-based artificial antigen-presenting cells for cancer immunotherapy","volume":"257","author":"Butler","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2018.02.016","article-title":"Nanoscale artificial antigen presenting cells for cancer immunotherapy","volume":"98","author":"Rhodes","year":"2018","journal-title":"Mol. Immunol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2217\/nnm-2016-0316","article-title":"Magnetic nanoparticles for precision oncology: Theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy","volume":"12","author":"Zhu","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2010.05.006","article-title":"Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy","volume":"63","author":"Mahmoudi","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrd2591","article-title":"Strategies in the design of nanoparticles for therapeutic applications","volume":"9","author":"Petros","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10611869808997890","article-title":"Superparamagnetic agents in magnetic resonance imaging: Physicochemical characteristics and clinical applications. A review","volume":"6","author":"Bonnemain","year":"1998","journal-title":"J. Drug Target."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7150\/thno.3463","article-title":"Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy","volume":"2","author":"Yu","year":"2012","journal-title":"Theranostics"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1002\/adma.201400158","article-title":"Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer","volume":"26","author":"Wang","year":"2014","journal-title":"Adv. Mater."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.biomaterials.2008.04.023","article-title":"On the mechanisms of biocompatibility","volume":"29","author":"Williams","year":"2008","journal-title":"Biomaterials"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2012.12.013","article-title":"Biocompatibility of engineered nanoparticles for drug delivery","volume":"166","author":"Naahidi","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1021\/bc200362a","article-title":"Synthesis and in vivo evaluation of the biodistribution of a 18F-labeled conjugate gold-nanoparticle-peptide with potential biomedical application","volume":"23","author":"Guerrero","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.addr.2004.09.003","article-title":"Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens","volume":"57","author":"Jiang","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.smim.2007.11.004","article-title":"Foreign body reaction to biomaterials","volume":"20","author":"Anderson","year":"2008","journal-title":"Semin. Immunol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1021\/acs.bioconjchem.6b00657","article-title":"Comprehensive and Systematic Analysis of the Immunocompatibility of Polyelectrolyte Capsules","volume":"28","author":"Zyuzin","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1016\/j.biomaterials.2013.07.102","article-title":"Preformed albumin corona, a protective coating for nanoparticles based drug delivery system","volume":"34","author":"Peng","year":"2013","journal-title":"Biomaterials"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.colsurfb.2012.10.039","article-title":"The Vroman effect: Competitive protein exchange with dynamic multilayer protein aggregates","volume":"103","author":"Hirsh","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1039\/c2nr33611a","article-title":"Protein corona formation for nanomaterials and proteins of a similar size: Hard or soft corona? View project","volume":"5","author":"Liu","year":"2014","journal-title":"Nanoscale"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nri3479","article-title":"Newly described pattern recognition receptors team up against intracellular pathogens","volume":"13","author":"Broz","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nri.2015.8","article-title":"Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease","volume":"16","author":"Cao","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm3999","article-title":"Live to die another way: Modes of programmed cell death and the signals emanating from dying cells","volume":"16","author":"Fuchs","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrrheum.2015.60","article-title":"Perception of self: Distinguishing autoimmunity from autoinflammation","volume":"11","author":"Wenink","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fcell.2019.00050","article-title":"Immunogenic cell death and immunotherapy of multiple myeloma","volume":"7","author":"Anel","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cytogfr.2013.01.005","article-title":"Inducers of immunogenic cancer cell death","volume":"24","author":"Dudek","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5301\/tj.5000675","article-title":"The inducers of immunogenic cell death for tumor immunotherapy","volume":"104","author":"Li","year":"2018","journal-title":"Tumori J."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1141>3.0.CO;2-X","article-title":"Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells","volume":"91","author":"Kurokawa","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/ijc.28766","article-title":"High hydrostatic pressure induces immunogenic cell death in human tumor cells","volume":"135","author":"Fucikova","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00262-011-1184-2","article-title":"Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin","volume":"61","author":"Garg","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molcel.2014.03.003","article-title":"Mixed Lineage Kinase Domain-like Protein MLKL Causes Necrotic Membrane Disruption upon Phosphorylation by RIP3","volume":"54","author":"Wang","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"e1149673","DOI":"10.1080\/2162402X.2016.1149673","article-title":"Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy","volume":"5","author":"Yang","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.celrep.2016.03.037","article-title":"Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity","volume":"15","author":"Aaes","year":"2016","journal-title":"Cell Rep."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death in Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1158\/0008-5472.CAN-10-1825","article-title":"Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death","volume":"70","author":"Zappasodi","year":"2010","journal-title":"Cancer Res."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1038\/cddis.2010.82","article-title":"Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia","volume":"1","author":"Wemeau","year":"2010","journal-title":"Cell Death Dis."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3748\/wjg.v16.i19.2428","article-title":"Expression of calreticulin is associated with infiltration of T-cells in stage III B colon cancer","volume":"16","author":"Peng","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_270","first-page":"1573","article-title":"Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice","volume":"334","author":"Michaud","year":"2011","journal-title":"Science 80"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-030409-101323","article-title":"HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection","volume":"29","author":"Andersson","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1084\/jem.201002692084c","article-title":"Contribution of IL-17-producing \u03b3\u03b4 T cells to the efficacy of anticancer chemotherapy","volume":"208","author":"Ma","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1021\/acs.nanolett.7b03218","article-title":"Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy","volume":"17","author":"Fan","year":"2017","journal-title":"Nano Lett."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"eaao1736","DOI":"10.1126\/sciadv.aao1736","article-title":"Elimination of established tumors with nanodisc-based combination chemoimmunotherapy","volume":"4","author":"Kuai","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"Bear, A.S., Kennedy, L.C., Young, J.K., Perna, S.K., Mattos Almeida, J.P., Lin, A.Y., Eckels, P.C., Drezek, R.A., and Foster, A.E. (2013). Elimination of Metastatic Melanoma Using Gold Nanoshell-Enabled Photothermal Therapy and Adoptive T Cell Transfer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069073"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms12499","article-title":"Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"7","author":"He","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/nnano.2017.113","article-title":"Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy","volume":"12","author":"Min","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"143ra99","DOI":"10.1126\/scitranslmed.3003807","article-title":"Cardiac glycosides exert anticancer effects by inducing immunogenic cell death","volume":"4","author":"Menger","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/onc.2010.500","article-title":"Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress","volume":"30","author":"Martins","year":"2011","journal-title":"Oncogene"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-18-0214","article-title":"Predictive biomarkers for checkpoint immunotherapy: Current status and challenges for clinical application","volume":"6","author":"Tray","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Spencer, K.R., Wang, J., Silk, A.W., Ganesan, S., Kaufman, H.L., and Mehnert, J.M. (2016). Biomarkers for Immunotherapy: Current Developments and Challenges. Am. Soc. Clin. Oncol. Educ. B., e493\u2013e503.","DOI":"10.14694\/EDBK_160766"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"789069","DOI":"10.1155\/2014\/789069","article-title":"The \u201cTrojan Horse\u201d Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment","volume":"2014","author":"Nelson","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: Volume I-pre-analytical and analytical validation","volume":"4","author":"Masucci","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_285","unstructured":"FDA-NIH Biomarker Working Group (2017). BEST (Biomarkers, EndpointS, and Other Tools)."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_287","first-page":"3317","article-title":"Serum Level of Interleukin 6 as a Prognosis Factor in Metastatic Renal Cell Carcinoma","volume":"52","author":"May","year":"1992","journal-title":"Cancer Res."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1200\/JCO.1996.14.5.1697","article-title":"Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multiinstitutional study","volume":"14","author":"Tartour","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2008.19.1106","article-title":"Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy","volume":"27","author":"Sabatino","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00262-014-1545-8","article-title":"Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma","volume":"63","author":"Simeone","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/cr.2015.3","article-title":"Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25","volume":"25","author":"Hannani","year":"2015","journal-title":"Cell Res."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","article-title":"The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures","volume":"39","author":"Galon","year":"2013","journal-title":"Immunity"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0243-4","article-title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","volume":"5","author":"Gnjatic","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bjc.6602702","article-title":"Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model","volume":"93","author":"Schmidt","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2004-06-2482","article-title":"Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy","volume":"105","author":"Powell","year":"2005","journal-title":"Blood"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1084\/jem.20040717","article-title":"CD27 Expression Promotes Long-Term Survival of Functional Effector\u2013Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients","volume":"200","author":"Ochsenbein","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2326-6066.CIR-13-0133","article-title":"PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection","volume":"2","author":"MacFarlane","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1073\/pnas.1110814108","article-title":"Integrated NY-ESO-1 antibody and CD8 + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab","volume":"108","author":"Yuan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-60327-811-9_1","article-title":"Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer","volume":"520","author":"Zhang","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0002-9440(10)61770-1","article-title":"Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis","volume":"159","author":"Lu","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1038\/sj.onc.1205625","article-title":"Cloning and characterization of a novel 90 kDa \u201ccompanion\u201d auto-antigen of p62 overexpressed in cancer","volume":"21","author":"Hoo","year":"2002","journal-title":"Oncogene"},{"key":"ref_303","first-page":"1672","article-title":"Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy","volume":"72","author":"Noguchi","year":"2012","journal-title":"AACR"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fimmu.2015.00067","article-title":"Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity","volume":"6","author":"Germain","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","article-title":"Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer","volume":"189","author":"Germain","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_306","unstructured":"(2020, May 16). Videssa Breast | Detecci\u00f3n de C\u00e1ncer de Mama a Base de Sangre. Available online: https:\/\/www.provistadx.com\/videssa-breast."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00262-007-0304-5","article-title":"In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients","volume":"56","author":"Bernsen","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive assessment of T-cell receptor \u03b2-chain diversity in \u03b1\u03b2 T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_314","first-page":"207","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Miao","year":"2015","journal-title":"Science 80"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1056\/NEJMc1508163","article-title":"Correction: Genetic basis for clinical response to CTLA-4 blockade in melanoma: To the editor","volume":"373","author":"Chan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"12297","DOI":"10.18632\/oncotarget.3655","article-title":"Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy","volume":"6","author":"Cirenajwis","year":"2015","journal-title":"Oncotarget"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"e27884","DOI":"10.4161\/onci.27884","article-title":"Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy","volume":"3","author":"Stoll","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/gcc.22733","article-title":"Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions","volume":"58","author":"Stenzinger","year":"2019","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and search for new cancer genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_321","first-page":"1","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Health","year":"2013","journal-title":"Nature"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.7150\/thno.21471","article-title":"Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_325","first-page":"56","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science 80"},{"key":"ref_326","first-page":"587","article-title":"An Antigenic Peptide Produced by Peptide Splicing in the Proteasome","volume":"304","author":"Vigneron","year":"2004","journal-title":"Science 80"},{"key":"ref_327","doi-asserted-by":"crossref","unstructured":"Madsen, C.B., Petersen, C., Lavrsen, K., Harndahl, M., Buus, S., Clausen, H., Pedersen, A.E., and Wandall, H.H. (2012). Cancer Associated Aberrant Protein O-Glycosylation Can Modify Antigen Processing and Immune Response. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050139"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"203ra125","DOI":"10.1126\/scitranslmed.3006061","article-title":"MHC Class I-Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia","volume":"5","author":"Cobbold","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"661","DOI":"10.21037\/tlcr.2018.08.02","article-title":"Methods of measurement for tumor mutational burden in tumor tissue","volume":"7","author":"Rorive","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","article-title":"Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration","volume":"22","author":"Ock","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying Cancers Based on T-cell Infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","article-title":"Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation","volume":"4","author":"Bald","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: A synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_338","first-page":"582","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science 80"},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"e29244","DOI":"10.4161\/onci.29244","article-title":"Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes","volume":"3","author":"Robert","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21037\/atm.2016.06.17","article-title":"Neoantigen-based cancer immunotherapy","volume":"4","author":"Bobisse","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_341","first-page":"1081","article-title":"Exploiting the Mutanome for Tumor Vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"AACR"},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma","volume":"31","author":"Philips","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_343","first-page":"1125","article-title":"Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer","volume":"20","author":"Wick","year":"2014","journal-title":"Hum. Cancer Biol."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"ref_345","first-page":"1546","article-title":"Cancer Genome Landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science 80"},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood"},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jim.2010.10.011","article-title":"Prediction of epitopes using neural network based methods","volume":"374","author":"Lundegaard","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3389\/fimmu.2017.01848","article-title":"Neoantigen targeting\u2014Dawn of a new era in cancer immunotherapy?","volume":"8","author":"Wirth","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ijc.25283","article-title":"Immune evasion of microsatellite unstable colorectal cancers","volume":"127","author":"Kloor","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"942","DOI":"10.15252\/msb.20156297","article-title":"Revisiting biomarker discovery by plasma proteomics","volume":"13","author":"Geyer","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"1700284","DOI":"10.1002\/pmic.201700284","article-title":"Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection","volume":"18","author":"Fritsche","year":"2018","journal-title":"Proteomics"},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nbt.2708","article-title":"The regulatory landscape for actively personalized cancer immunotherapies","volume":"31","author":"Britten","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1084\/jem.20071985","article-title":"The MHC class I peptide repertoire is molded by the transcriptome","volume":"205","author":"Fortier","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1074\/mcp.M600310-MCP200","article-title":"Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface","volume":"6","author":"Weinzierl","year":"2007","journal-title":"Mol. Cell. Proteom."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"18769","DOI":"10.1073\/pnas.1008501107","article-title":"Soluble plasma HLA peptidome as a potential source for cancer biomarkers","volume":"107","author":"Barnea","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nm0996-1005","article-title":"Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes","volume":"2","author":"Zavazava","year":"1996","journal-title":"Nat. Med."},{"key":"ref_360","unstructured":"(2020, May 18). HUPO-Proyecto de Inmunop\u00e9ptido Humano. Available online: https:\/\/hupo.org\/human-immuno-peptidome-project\/."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"D1237","DOI":"10.1093\/nar\/gkx664","article-title":"The SysteMHC Atlas project","volume":"46","author":"Shao","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00251-015-0873-y","article-title":"Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification","volume":"67","author":"Andreatta","year":"2015","journal-title":"Immunogenetics"},{"key":"ref_363","doi-asserted-by":"crossref","unstructured":"Nielsen, M., and Lund, O. (2009). NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinform., 10.","DOI":"10.1186\/1471-2105-10-296"},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"D405","DOI":"10.1093\/nar\/gku938","article-title":"The immune epitope database (IEDB) 3.0","volume":"43","author":"Vita","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0065-2776(08)60641-0","article-title":"Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology","volume":"44","author":"Tan","year":"1989","journal-title":"Adv. Immunol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ijc.2910300404","article-title":"Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer","volume":"30","author":"Crawford","year":"1982","journal-title":"Int. J. Cancer"},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-065X.2008.00611.x","article-title":"Autoantibodies to tumor-associated antigens: Reporters from the immune system","volume":"222","author":"Tan","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2249.2003.02259.x","article-title":"Relative paradigms between autoantibodies in lupus and autoantibodies in cancer","volume":"134","author":"Tan","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nm0795-701","article-title":"Serum p53 antibodies as early markers of lung cancer","volume":"1","author":"Lubin","year":"1995","journal-title":"Nat. Med."},{"key":"ref_370","first-page":"1767","article-title":"Anti-p53 Antibodies in Sera from Patients with Chronic Obstructive Pulmonary Disease Can Predate a Diagnosis of Cancer","volume":"2","author":"Trivers","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/jnci\/87.18.1400","article-title":"Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride","volume":"87","author":"Trivers","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1097-0142(19930101)71:1<26::AID-CNCR2820710106>3.0.CO;2-N","article-title":"Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma","volume":"71","author":"Imai","year":"1993","journal-title":"Cancer"},{"key":"ref_373","first-page":"209","article-title":"Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells","volume":"2","author":"Woessner","year":"1991","journal-title":"Cell Growth Differ."},{"key":"ref_374","first-page":"4168","article-title":"Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation","volume":"52","author":"Winter","year":"1992","journal-title":"Cancer Res."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-04-0538","article-title":"T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"D769","DOI":"10.1093\/nar\/gkw946","article-title":"AAgAtlas 1.0: A human autoantigen database","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.4049\/jimmunol.166.11.6555","article-title":"Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection","volume":"166","author":"Soares","year":"2001","journal-title":"J. Immunol."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1084\/jem.194.9.1313","article-title":"Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells","volume":"194","author":"Kao","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_379","unstructured":"Wild, D. (2013). The Immunoassay Handbook: Theory and Applications of Ligand Binding, ELISA and Related Techniques, Newnes."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trac.2016.04.018","article-title":"Mass spectrometry methods in clinical diagnostics\u2014State of the art and perspectives","volume":"84","author":"Vogeser","year":"2016","journal-title":"TrAC-Trends Anal. Chem."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21037\/cco.2018.01.03","article-title":"Immunoregulatory antigens\u2014Novel targets for cancer immunotherapy","volume":"7","author":"Pedersen","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"e1356964","DOI":"10.1080\/2162402X.2017.1356964","article-title":"Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy","volume":"6","author":"Montico","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbcan.2009.08.003","article-title":"Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation","volume":"1805","author":"Garg","year":"2010","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1073\/pnas.1424829112","article-title":"Force-dependent transition in the T-cell receptor \u03b2-subunit allosterically regulates peptide discrimination and pMHC bond lifetime","volume":"112","author":"Das","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/2326-6066.CIR-15-0042","article-title":"\u03b1\u03b2 TCR-mediated recognition: Relevance to tumor-antigen discovery and cancer immunotherapy","volume":"3","author":"Reinherz","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.4049\/jimmunol.153.12.5586","article-title":"The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes","volume":"153","author":"Sette","year":"1994","journal-title":"J. Immunol."}],"container-title":["Nanomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4991\/10\/7\/1274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:44:35Z","timestamp":1760175875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4991\/10\/7\/1274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":387,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["nano10071274"],"URL":"https:\/\/doi.org\/10.3390\/nano10071274","relation":{},"ISSN":["2079-4991"],"issn-type":[{"value":"2079-4991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]}}}